Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
EDISON, N.J., December 02, 2008 /PRNewswire/ -- Daiichi Sankyo, Inc. , today announced that results from three studies of its investigational molecule, DU-176b, will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH), to be held December 6 - 9, 2008, in San Francisco. The data accepted for the ASH meeting are part of the clinical development of DU-176b, an oral Factor Xa inhibitor being investigated to prevent the formation of blood clots. Information on the studies to be presented at the meeting is as follows:
To arrange an interview with Francis Plat, MD, vice president, clinical development at Daiichi Sankyo Pharma Development, or Jeffrey Weitz, MD, FACP, FRCP, Professor of Medicine and Biochemistry, and Director, Henderson Research Centre, Hamilton, Ontario at the 2008 ASH Meeting in San Francisco, please contact Kim Wix, Daiichi Sankyo, at 973-695-8338 (office) 908-656-5447 (mobile) or Catherine Falcetti, MS&L, at 212-468-4337 (office) or 646-246-1843 (mobile).
DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.
A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. Equally important to the company is the discovery of new medicines in the areas of cancer, infectious diseases, bone and joint diseases, and immune disorders. For more information, visit www.daiichisankyo.com.
Daiichi Sankyo, Inc., a subsidiary of the global research-based pharmaceutical company, is based in Parsippany, NJ.
For more information, please contact: Kim Wix Daiichi Sankyo (U.S.A.) 973-695-8338 (office) 908-656-5447 (cell)
CONTACT: Kim Wix, Daiichi Sankyo (U.S.A.), +1-973-695-8338 (office),+1-908-656-5447 (cell)
Web site: http://www.daiichisankyo.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: December 2008